ValuEngine upgraded shares of Kindred Biosciences (NASDAQ:KIN) from a sell rating to a hold rating in a research report released on Friday.
A number of other equities analysts also recently commented on KIN. Zacks Investment Research downgraded shares of Kindred Biosciences from a buy rating to a hold rating in a report on Wednesday, October 11th. HC Wainwright began coverage on shares of Kindred Biosciences in a research report on Friday, November 17th. They set a buy rating and a $9.50 target price for the company. B. Riley reiterated a buy rating and set a $11.00 target price on shares of Kindred Biosciences in a research report on Monday, November 20th. Aegis reiterated a buy rating on shares of Kindred Biosciences in a research report on Friday, December 15th. Finally, BMO Capital Markets reiterated a hold rating on shares of Kindred Biosciences in a research report on Friday, December 22nd. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $9.63.
Kindred Biosciences (KIN) opened at $7.70 on Friday. Kindred Biosciences has a 1-year low of $5.00 and a 1-year high of $9.80.
In related news, Director Raymond Townsend sold 6,419 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $9.45, for a total transaction of $60,659.55. Following the completion of the sale, the director now owns 18,419 shares in the company, valued at approximately $174,059.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 19.10% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Kindred Biosciences by 57.7% in the 2nd quarter. Vanguard Group Inc. now owns 745,322 shares of the biopharmaceutical company’s stock valued at $6,410,000 after acquiring an additional 272,612 shares in the last quarter. General American Investors Co. Inc. acquired a new stake in Kindred Biosciences in the 3rd quarter valued at about $5,232,000. Wells Fargo & Company MN increased its position in Kindred Biosciences by 2.2% in the 3rd quarter. Wells Fargo & Company MN now owns 337,608 shares of the biopharmaceutical company’s stock valued at $2,650,000 after acquiring an additional 7,206 shares in the last quarter. New York State Common Retirement Fund increased its position in Kindred Biosciences by 19.1% in the 3rd quarter. New York State Common Retirement Fund now owns 265,543 shares of the biopharmaceutical company’s stock valued at $2,085,000 after acquiring an additional 42,500 shares in the last quarter. Finally, State Street Corp acquired a new stake in Kindred Biosciences in the 2nd quarter valued at about $2,209,000. Hedge funds and other institutional investors own 66.69% of the company’s stock.
Kindred Biosciences Company Profile
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.